Zacks Investment Research upgraded shares of Natus Medical Inc. (NASDAQ:BABY) from a sell rating to a hold rating in a research report report published on Monday morning.

According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “

Other equities research analysts have also recently issued research reports about the stock. Benchmark Co. started coverage on shares of Natus Medical in a report on Tuesday, October 4th. They issued a buy rating and a $55.00 price target on the stock. Raymond James Financial Inc. raised shares of Natus Medical from a market perform rating to an outperform rating and set a $46.00 price target on the stock in a report on Tuesday, September 13th.

Shares of Natus Medical (NASDAQ:BABY) opened at 42.00 on Monday. The firm has a market cap of $1.36 billion, a P/E ratio of 34.15 and a beta of 1.16. Natus Medical has a one year low of $29.54 and a one year high of $51.05. The firm has a 50 day moving average price of $40.74 and a 200-day moving average price of $38.82.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, October 19th. The company reported $0.39 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.05. The company had revenue of $90.90 million for the quarter, compared to analysts’ expectations of $89.94 million. Natus Medical had a net margin of 10.89% and a return on equity of 13.53%. Natus Medical’s revenue was down 3.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.39 EPS. Analysts forecast that Natus Medical will post $1.64 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and reposted in violation of international trademark & copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2016/11/29/natus-medical-inc-baby-upgraded-to-hold-at-zacks-investment-research.html.

In other news, insider James B. Hawkins purchased 10,000 shares of Natus Medical stock in a transaction dated Thursday, October 27th. The stock was purchased at an average cost of $38.30 per share, for a total transaction of $383,000.00. Following the transaction, the insider now directly owns 469,725 shares of the company’s stock, valued at $17,990,467.50. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Jonathan Kennedy sold 14,138 shares of the business’s stock in a transaction on Monday, October 24th. The shares were sold at an average price of $41.61, for a total transaction of $588,282.18. Following the transaction, the chief financial officer now owns 91,351 shares of the company’s stock, valued at $3,801,115.11. The disclosure for this sale can be found here. Insiders own 4.80% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp raised its position in Natus Medical by 2.2% in the first quarter. State Street Corp now owns 674,379 shares of the company’s stock worth $25,914,000 after buying an additional 14,617 shares during the period. Barclays PLC purchased a new position in Natus Medical during the first quarter worth approximately $959,000. BNP Paribas Arbitrage SA raised its position in Natus Medical by 120.8% in the second quarter. BNP Paribas Arbitrage SA now owns 10,316 shares of the company’s stock worth $390,000 after buying an additional 5,643 shares during the period. Capstone Asset Management Co. raised its position in Natus Medical by 9.9% in the second quarter. Capstone Asset Management Co. now owns 13,103 shares of the company’s stock worth $495,000 after buying an additional 1,180 shares during the period. Finally, Anderson Hoagland & Co. purchased a new position in Natus Medical during the second quarter worth approximately $1,571,000. Hedge funds and other institutional investors own 84.01% of the company’s stock.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

5 Day Chart for NASDAQ:BABY

Receive News & Stock Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related stocks with our FREE daily email newsletter.